LI
CBIO

Leap Investments’s Crescent Biopharma CBIO Stock Holding History

Leap Investments’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$92K Buy
245
+46
+23% +$13K 0.06% 356
2020
Q1 		$45K Buy
+199
New +$76.1K 0.07% 330

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Leap Investments's CBIO Position: Q2 2020 in Review

Leap Investments increased its Crescent Biopharma (CBIO) stake by 23% in Q2 2020, buying an estimated $13K and bringing the position to 245 shares worth $92K. The position accounts for 0.06% of the portfolio, ranked #356.

Leap Investments first reported a position in CBIO in Q1 2020 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold CBIO as of Q2 2020.

  • Leap Investments held 245 shares of Crescent Biopharma worth $92K as of Q2 2020.
  • Leap Investments bought 46 Crescent Biopharma shares in Q2 2020, an estimated $13K.
  • Crescent Biopharma made up 0.06% of Leap Investments's portfolio in Q2 2020, its #356 holding.
  • Leap Investments first reported a position in Crescent Biopharma in Q1 2020 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.